93 related articles for article (PubMed ID: 1674366)
1. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells.
Lin YZ; Clinton GM
Oncogene; 1991 Apr; 6(4):639-43. PubMed ID: 1674366
[TBL] [Abstract][Full Text] [Related]
2. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
[TBL] [Abstract][Full Text] [Related]
3. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
5. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer.
Valerón PF; Chirino R; Fernandez L; Torres S; Navarro D; Aguiar J; Cabrera JJ; Diaz-Chico BN; Diaz-Chico JC
Int J Cancer; 1996 Jan; 65(2):129-33. PubMed ID: 8567106
[TBL] [Abstract][Full Text] [Related]
6. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
7. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
Katdare M; Osborne M; Telang NT
Int J Oncol; 2002 Oct; 21(4):809-15. PubMed ID: 12239620
[TBL] [Abstract][Full Text] [Related]
8. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Masuda M; Suzui M; Lim JT; Weinstein IB
Clin Cancer Res; 2003 Aug; 9(9):3486-91. PubMed ID: 12960141
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
11. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
[TBL] [Abstract][Full Text] [Related]
12. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
13. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
14. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
15. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
[TBL] [Abstract][Full Text] [Related]
16. Disulfide-linked and noncovalent dimers of p185HER-2 in human breast carcinoma cells.
Lin YJ; Christianson TA; Clinton GM
J Cell Biochem; 1992 Jul; 49(3):290-5. PubMed ID: 1379605
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
18. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
19. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K
Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143
[TBL] [Abstract][Full Text] [Related]
20. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]